The cell membrane expression and functional role of the interleukin-2 receptor (IL-2R) was analyzed in nine patients with lymphoproliferative disease of granular lymphocytes (LDGL) using monoclonal antibodies (MoAbs) specific for the p75 (TU271 and the p55 (anti-lac) subunits of IL-2R. Four patients were characterized by the proliferation of CD3+ CD8 + granular lymphocytes (GL) expressing the a/j3 T-cell receptor (Tap) and one case by the proliferation of CD3+CD4-CD8-GL expressing the y/6 T-cell receptor (Ty8); in four additional cases proliferating cells were CD3 negative GL. Consistent with data observed on normal GL, phenotypic analysis demonstrated that patients' GL H E LYMPHOPROLIFERATIVE disease of granular T lymphocytes (LDGL) is a rare disorder characterized by a chronic proliferation of lymphocytes with azurophilic granules in their cytoplasm (granular lymphocytes, GL).'.2 From an immunologic and molecular viewpoint, LDGL patients can be separated into two g r o~p s .~ The first is represented by the proliferation of CD3 + GL, belonging to the T-cell lineage (CD3+ LDGL), and the other one by the proliferation of CD3 -GL, which belong to the natural killer (NK) cell system (CD3-LDGL). However, the clinical pattern in both groups of patients is similar and usually indolent.
T lymphocytes (LDGL) is a rare disorder characterized by a chronic proliferation of lymphocytes with azurophilic granules in their cytoplasm (granular lymphocytes, GL).'. 2 From an immunologic and molecular viewpoint, LDGL patients can be separated into two g r o~p s .~ The first is represented by the proliferation of CD3 + GL, belonging to the T-cell lineage (CD3+ LDGL), and the other one by the proliferation of CD3 -GL, which belong to the natural killer (NK) cell system (CD3-LDGL). However, the clinical pattern in both groups of patients is similar and usually indolent.
Recent data demonstrated that expanding cells in LDGL patients are highly responsive to interleukin-2 (IL-2) stimulation as they display cytotoxic activity and cell proliferation in vitro following the trigger with this lymph~kine.~.~ Because in these cases G L do not spontaneously express the CD25/ Tac ie, the p55(a) chain of IL-2 receptor (IL-2R), it has been suggested that the response to IL-2 is mediated by a different IL-2 binding p r~t e i n .~.~ In fact, cross-linking experiments and schatchard plot analysis using I2'I labeled IL-2 provided indirect evidence for the presence of a 70/75 Kd protein structure with intermediate affinity for IL-2 on G L ~u r f a c e .~'~ Provided that fully functional high affinity IL-2R are generated by the association of p55 and p75 lack the expression of the p55 IL-2R. whereas the p75 subunit is constitutionally expressed by expanding GL of both T-cell (either Tap and Ty6) and natural killer (NK) origin in variable proportions (11% to 94% of cells). The analysis of the cytotoxic and proliferative activity demonstrated that the anti-p55 MoAb failed to inhibit IL-2-mediated activation, whereas a marked inhibition of both cytotoxicity and proliferation were obtained using the anti-p75 chain specific MoAb. These data indicate that the p75 chain of IL-2R is responsible for IL-2 signal transduction in both CD3+ and CD3-LDGL patients' GL. 0 1990 by The American Society of Hematology.
chains, the p75(@) subunit alone has been demonstrated to be able to transduce the activation signaL4*' Recently, monoclonal antibodies (MoAbs) have been generated which recognize the p75 IL-2R, thus giving the opportunity to directly evaluate the role of this molecule on IL-2 mediated activation pathway^.^.^ In this study, using the TU27 MoAb,' we have investigated the presence of the p75 IL-2R on G L and its specific function on cell activation in a series of LDGL patients characterized by the proliferation of CD3+ GL, either expressing the T-cell receptor a/P (Tab) or the T-cell receptor y/S (TyS), or by the proliferation of CD3 negative GL.
MATERIALS AND METHODS
Nine patients with LDGL were studied. Diagnosis of LDGL was based on previously reported criteria.* All patients were asymptomatic and untreated at the time of study, with the only exception being case no. 8, who suffered from autoimmune hemolytic anemia. In this patient, steroid therapy was withdrawn one month before this study was performed. Table 1 summarizes the clinical and immunological findings of cases under study.
The following fluorescein (FITC) or phycoerhytrin (PE)-conjugated MoAbs were used: anti-CD3 (OKT3), antLCD4 (OKT4), antLCD8 (OKT8) (Ortho Diagnostic, Raritan, NJ); anti-CD16 (Leu1 la), anti-TCR1 (WT31), and anti-CD14 (Leu M3) and anti-CD22 (Leu 14) (Becton Dickinson Sunnyvale, CA); TCRGl and GTCSl MoAbs (T Cell Science Cambridge, MA); BB3 MoAb, which reacts with an idiotipic determinant of the 6 chain" was a gift of Dr L. Moretta (Genova, Italy); ascitic fluid containing anti-CD25 (anti-Tac) MoAb that recognizes the p55 IL-2-R and blocks IL-2 binding to this subunit" was a gift of Dr T. Uchiyama (Kyoto, Japan); ascitic fluid containing TU27 MoAb, which reacts with the p75 molecule of IL-2 receptor and blocks IL-2 binding to this subunit: was a gift of Prof K. Sugamura (Tohoku, Japan) and Dr S. Taki (Kawasaki, Japan). In the functional studies, anti-Tac and TU27 MoAbs were used at 1500 and 1:400 final dilution of ascitic fluid, respectively. In preliminary experiments, these doses were demonstrated to provide a 70% inhibition of phytohemagglutinin-mediated proliferation of normal peripheral blood lymphocytes.
Peripheral blood mononuclear cells (PBMC) were isolated through a Ficoll-Hypaque gradient and washed twice in phosphate buffered saline. The resulting cell population was represented by 70% to 95% of GL, as evaluated by May-Grunwald Giemsa stained cytospins. Cells were cultured in RPMI 1640
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Cell cultures. (GIBCO, UK) with 10% fetal calf serum (FCS, Flow Laboratories) and 1% streptomycin/penicillin.
In some experiments, GL were further purified by using a complement-mediated lysis technique, as previously reported.'* In cases no. 2 and 4 (type CD3-LDGL), 89% and 87% of peripheral blood lymphocytes, respectively, showed the typical GL morphology. Highly enriched GL (more than 97%) were obtained by eliminating the CD3 + , CDI 4 + , and CD22 + cells (residual normal T lymphocytes, monocytes and B lymphocytes, respectively). In case no. 8 (type CD3+ LDGL), 90% of peripheral blood lymphocytes were represented by GL. Two color immunofluorescent flow cytometry analysis demonstrated that 98% of CD8+ cells coexpressed the CD16 marker, as proof that these cells belong to the abnormal GL population. GL were enriched in this patient by using complement mediated lysis of CD4+, CD14+, and CD22+ lymphocytes to obtain a final population consisting of more than 97% GL. The majority of cells obtained with these procedures (>95%) were viable when tested by trypan blue exclusion.
Cytotoxic activity was assessed by the lysis of 51Cr labeled NK sensitiye K-562 targets or NK resistant Raji targets in a 4-hour assay, as previously reported in detail." Lytic function of GL was analyzed both at resting conditions and following in vitro activation of lymphocytes (106/mL) with 100 U/mL of rIL-2 (Glaxo Institute for Molecular Biology, Geneva, Switzerland) for 72 hours at 37OC in 5% CO, atmosphere. Results are expressed as lytic units (LU) times IO' effector cells for 30% specific lysis of IO4 target cells. '4 Cells at the concentration of 1 x IO6 cells/mL were cultured in 96 round bottom well plates for 72 hours at 37OC in 5% CO, atmosphere with rIL-2 (100 U/mL). Each experiment was carried out in triplicate. For the last 18 hours of culture, plates were pulsed with 1 pCi/well of 'H-thymidine (CEA, IRE, Sorin, Italy); cells were then harvested and the radioactivity measured with a /3 counter. Results are expressed as counts per minute (cpm) 2 standard error of the mean (SEM).
A panel of FITC and PE conjugated MoAbs was used for direct one-and two-color analysis, as previously reported in detail.I5 Because the expression of the p75 IL-2R on cell surface is faint, an amplification system consisting of a biotinilated second antibody (goat anti-mouse IgGI, Boehringer Mannheim, FRG) and PE-conjugated streptavidin (Becton Dickinson) was used. When double staining experiments were performed, a FITC-conjugated MoAb as a third step or isotype matched control IgG was added together with PE streptavidin. When the third antibody belonged to the IgGl subclass, free ligand Cytotoxic assay.
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sites of biotinilated goat anti-mouse were blocked using mouse serum (Dakopatts, Denmark). Cells were analyzed using a FACScan analyzer (Becton Dickinson, Sunnyvale, CA) and data were processed by using the Consort 30 program. Ten thousand cells bearing the typical lymphocyte scatter were scored.
Data are expressed as mean 2 SEM and comparisons between values made using the Cochran-Cox analysis.
A value of P -= .OS was accepted as significant. 
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RESULTS
Phenotypic
cells). T h e expression of T U 2 7 MoAb
showed different patterns of positivity (Fig l ) , possibly related to the different densities of the p75 IL-2R on GL surface. Examination of the contour plots (Fig 2) , demonstrated the coexpression on cell surface of the p75 IL-2R and CD16+ in CD3-LDGL patients and of p75 IL-2R and CD8+ on CD3+Tafi+ LDGL patients. In both groups, C D 4 + cells were T U 2 7 negative. I n case no. 9, TCRGl+CD4-CD8-GL were shown to express the p75 IL-2R, which was not detected on C D 4 + and CD8+ cells.
Eflect of anti-p75 IL-2R MoAb on activation of patients'
GL. As shown in Fig 3A, F l u o r e s c e n c e ( 3 d e c a d e log) strated low baseline cytotoxicity against the K-562 target cells, which could be boosted by rIL-2. While anti-Tac MoAb did not provide any effect on cytotoxic function, the addition of TU27 MoAb dramatically inhibited the IL-2 induced cytotoxicity in these cases. Since GL of CD3-LDGL patients expressed high basal values of cytotoxicity against the K562 target cells (275 LU, 71 1 LU, 147 LU and 73 LU for patients no. 1, 2, 3, and 4, respectively), the NK-resistant Raji targets were used to test the cytotoxicity induced by IL-2. At baseline conditions, three cases showed low levels of lysis against the Raji targets, whereas in case no. 3 , GL were spontaneously cytotoxic for these targets (81 LU). The addition of TU27 MoAb to the culture markedly inhibited the IL-2 induced lytic activity also in these CD3-cases. Neither anti-p75 IL-2R nor anti-p55 IL-2R MoAb affected the cytotoxicity against target cells mediated by (Fig 3B) and, to a greater extent, by TU27 MoAb. Although anti-p55 IL-2R MoAb alone did not significantly modify the IL-2 induced proliferative activity in both CD3+ and CD3-LDGL patients, in the majority of cases the combination of anti-p55 and anti-p75 IL-2R MoAbs provided a synergistic effect in inhibiting the 'H-Thymidine incorporation, the phenomenon being more evident in CD3 -cases.
To rule out the possibility that normal residual lymphocytes and not the abnormal GL population may account for the findings associated with IL-2 mediated activation, highly purified GL were studied in three representative patients (two CD3 -and one CD3 + LDGL) in the same experimental conditions. As shown in Fig 4, the patterns observed for the cytotoxic and proliferative abilities were consistent with those shown using PBMC, with the exception of patient no. 8, in whom a relevant inhibition of proliferative activity of CD3-CD3+crp+ CD3+ yd+ controls LDGL patients purified CD3+ GL was demonstrated by anti-p55 IL-2R MoAb.
DISCUSSION
In this study we demonstrated that in patients with LDGL proliferating GL constitutionally express the p75 IL-2R. Both CD3+ (either Tap or TyS) and CD3-GL are equipped with p75 IL-2R, whereas detectable levels of surface p55 IL-2R were not found on cell surface. Using MoAb to the p75 IL-2R, we provided direct evidence that the initial events leading to the 1L-2 activation of GL in LDGL patients are mediated by the p75 chain of IL-2R.
Previous reports on LDGL patients had already suggested that the IL-2 activation was mediated through the p75 IL-2R. Recent studies on the expression of the p75 IL-2R using MoAbs have demonstrated that the majority of normal CD16+ circulating lymphocytes (NK cells) and a variable percentage of CD3+ T lymphocytes (mostly CD8+aj3+ or CD4-CD8-76+ Tcells) constitutionally expressed the p75 IL-2R,I8-'" although this point is still controversial.2' Because these cell populations represent discrete subsets with low frequency in peripheral blood, further studies are needed to precisely characterize these cells for the presence and the kinetic of expression of membrane p75 IL-2R either in the blood or in other compartments. To explain the findings that CD8+ cells do not express the p75 IL-2R, an alternative hypothesis supports the fact that residual T cells in this disorder are to some extent abnormal. Taken together, our data indicate that the expression and the functional properties of the p75 IL-2R are maintained in the pathologic counterparts of cells with which we are dealing, pointing to a possible role for the p75 IL-2R on the abnormal proliferation of GL. In this regard, although LDGL encompasses a wide spectrum of clinical, immunologic and biologic conditions,'.' the expression of the p75 IL-2R represents a consistent Interestingly enough, although anti-pS5 IL-2R MoAb did not significantly inhibit the IL-2-induced cytotoxicity against the targets used and exerted only a minimal effect on the IL-2 mediated proliferative activity, the combination of anti-p75 and anti-pS5 IL-2R MoAbs showed slightly higher levels of inhibition than those detected in experiments using anti-p75 IL-2R MoAb alone, particularly in terms of induction of the proliferative activity of CD3-cases (Fig 3) . As to cytotoxic function, the pattern is more evident following enrichment of G L (Fig 4B) . The differences in blocking experiments using anti-p75 IL-2R MoAb as compared with the combination are not statistically significant, perhaps because of the low number of cases studied. However, it is tempting to suggest that low levels of the p55 IL-2R subunit, possibly not detectable by flow cytometry, are expressed and functional on G L of patients, irrespective of their T-cell or NK-cell origin. According to this interpretation we have recently shown in LDGL patients that IL-2 is able to stimulate the synthesis of mRNA for p55 IL-2R in CD3+ G L even in the absence of a detectable CD25 antigen on cell surface of cells under study (manuscript in preparation).
In conclusion, the results obtained from the present study directly implicate the p75 IL-2R as the structure responsible 
